MedTrace Logo

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

NCT01024920 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2021-07-19

Study results available
· View outcomes & findings →

Summary

Compare safety and efficacy of BIBF 1120 versus sunitinib in patients with advanced RCC and to investigate the effects of BIBF 1120 on the heart rate (HR) corrected QT interval (QTcF).

Conditions

  • Carcinoma, Renal Cell

Interventions

DRUG

BIBF 1120

VEGF inhibitor

DRUG

sunitinib

VEGF inhibitor

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-16
Primary Completion
2011-11-08
Completion
2020-06-19

Countries

  • Hungary
  • Poland
  • Romania
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01024920 on ClinicalTrials.gov